| No. of patients (%) | |
| Median age, years | 64 (range 42-91) |
| Age | |
| < 60 years | 11 (42%) |
| > 60 years | 15 (58%) |
| Preoperative Karnofsky performance status | |
| > 80 | 17 (65%) |
| < 80 | 15 (58%) |
| Preoperative haemoglobin (Hb) level | |
| > 10 mg/dl | 15 (58%) |
| < 10 mg/dl | 11 (42%) |
| Preoperative platelet counts | |
| < 200 G/L | 3 (12%) |
| > 200 G/L | 23 (88%) |
| Preoperative lactate dehydrogenase (LDH) level | |
| < 200 U/L | 4 (15%) |
| > 200 U/L | 20 (77%) |
| Not determined | 2 (8%) |
| Preoperative ultrasound | |
| Solid-cystic tumour | 18 (69%) |
| Cystic tumour with papillary projections | 7 (27%) |
| No suspicious findings of the adnexae | 1 (4%) |
| FIGO stage | |
| Ib | 1 (4%) |
| Ic | 2 (8%) |
| IIb | 1 (4%) |
| IIIa | 3 (12%) |
| IIIb | 1 (4%) |
| IIIc | 18 (69%) |
| Intraoperative ascites | |
| None | 8 (31%) |
| < 500 ml | 9 (35%) |
| > 500 ml | 9 (35%) |
| Bowel involvement | |
| Small bowel | 6 (23%) |
| Large bowel | 9 (35%) |
| Sigmoid colon/rectum | 13 (50%) |
| Primary surgery | |
| Bilateral salpingo-oophorectomy (BSO)+ total abdominal hysterectomy (TAH) + omentectomy (OM) | 14 (54%) |
| BSO + TAH + OM + pelvic lymphadenectomy | 12 (46%) |
| Residual disease | |
| None | 18 (69%) |
| < 1 cm | 1 (4%) |
| < 2 cm | 2 (8%) |
| > 2 cm | 5 (19 %) |
| Sarcoma component | |
| Homologous | 7 (27%) |
| Heterologous | 19 (73%) |
| Grading | |
| G1 | 1 (4%) |
| G2 | 2 (8%) |
| G3 | 23 (77%) |
| Chemotherapy | |
| Platinum-based | 18 (69%) |
| Non-platinum-based | 1 (4%) |
| None* | 7 (27%) |